Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Retained Earnings (2024 - 2025)

Prelude Therapeutics' Retained Earnings history spans 2 years, with the latest figure at $8000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings fell 77.14% year-over-year to $8000.0; the TTM value through Dec 2025 reached $8000.0, down 77.14%, while the annual FY2025 figure was $8000.0, 77.14% down from the prior year.
  • Retained Earnings for Q4 2025 was $8000.0 at Prelude Therapeutics, up from -$666.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $167000.0 in Q3 2024 and bottomed at -$666.6 million in Q3 2025.